288296-64-0 Usage
Uses
Used in Pharmaceutical Industry:
BIS THF Nitro Derivative 1 is used as an impurity in the development and production of HIV-aspartyl protease inhibitors. These inhibitors are crucial in the treatment of HIV, as they help to prevent the replication of the virus within the body. The presence of BIS THF Nitro Derivative 1 in these compounds can impact their efficacy and safety, making it essential to monitor and control its levels during the manufacturing process.
Used in Research and Development:
BIS THF Nitro Derivative 1 is used as a research tool for studying the properties and behavior of bis-THF-derived compounds. Understanding the role of this impurity can help researchers optimize the synthesis and purification processes of HIV-aspartyl protease inhibitors, ultimately leading to more effective treatments for HIV.
Used in Quality Control and Analysis:
BIS THF Nitro Derivative 1 is used in the quality control and analysis of HIV-aspartyl protease inhibitors. By monitoring the levels of this impurity, manufacturers can ensure that the final product meets the required safety and efficacy standards. This helps to maintain the overall quality of the drug and minimize any potential adverse effects on patients.
Check Digit Verification of cas no
The CAS Registry Mumber 288296-64-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,2,9 and 6 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 288296-64:
(8*2)+(7*8)+(6*8)+(5*2)+(4*9)+(3*6)+(2*6)+(1*4)=200
200 % 10 = 0
So 288296-64-0 is a valid CAS Registry Number.
288296-64-0Relevant academic research and scientific papers
Crystalline Darunavir
-
Paragraph 0059, (2014/12/09)
The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.
Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors
Chen, Xiaoqi,Li, Lin,Kempf, Dale J.,Sham, Hing,Wideburg, Norman E.,Saldivar, Ayda,Vasavanonda, Sudthida,Marsh, Kennan C.,McDonald, Edith,Norbeck, Daniel W.
, p. 2847 - 2852 (2007/10/03)
The hexahydrofurofuranyloxy group was evaluated as a conformationally constrained P2 ligand for symmetry-based HIV protease inhibitors. A number of compounds showed nM level activity against HIV in MT4 cells and lower protein binding than the licensed protease inhibitor ritonavir. However, replacement of 5-thiazole of ritonavir with a furofuran caused a reduction of the bioavailability in vivo.
